Distinct antitumor properties of a type IV collagen domain derived from basement membrane.
Vascular basement membrane is an important structural component of blood vessels. During angiogenesis this membrane undergoes many alterations and these changes are speculated to influence the formation of new capillaries. Type IV collagen is a major component of vascular basement membrane, and recently we identified a fragment of type IV collagen alpha2 chain with specific anti-angiogenic properties (Kamphaus, G. D., Colorado, P. C., Panka, D. J., Hopfer, H., Ramchandran, R., Torre, A., Maeshima, Y., Mier, J. W., Sukhatme, V. P., and Kalluri, R. (2000) J. Biol. Chem. 275, 1209-1215). In the present study we characterize two different antitumor activities associated with the noncollagenous 1 (NC1) domain of the alpha3 chain of type IV collagen. This domain was previously discovered to possess a C-terminal peptide sequence (amino acids 185-203) that inhibits melanoma cell proliferation (Han, J., Ohno, N., Pasco, S., Monboisse, J. C., Borel, J. P., and Kefalides, N. A. (1997) J. Biol. Chem. 272, 20395-20401). In the present study, we identify the anti-angiogenic capacity of this domain using several in vitro and in vivo assays. The alpha3(IV)NC1 inhibited in vivo neovascularization in matrigel plug assays and suppressed tumor growth of human renal cell carcinoma (786-O) and prostate carcinoma (PC-3) in mouse xenograft models associated with in vivo endothelial cell-specific apoptosis. The anti-angiogenic activity was localized to amino acids 54-132 using deletion mutagenesis. This anti-angiogenic region is separate from the 185-203 amino acid region responsible for the antitumor cell activity. Additionally, our experiments indicate that the antitumor cell activity is not realized until the peptide region is exposed by truncation of the alpha3(IV)NC1 domain, a requirement not essential for the anti-angiogenic activity of this domain. Collectively, these results effectively highlight the distinct and unique antitumor properties of the alpha3(IV)NC1 domain and the potential use of this molecule for inhibition of tumor growth.
Maeshima
Y
Y
Department of Medicine/Pathology and the Cancer Center, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA.
Colorado
P C
PC
Torre
A
A
Holthaus
K A
KA
Grunkemeyer
J A
JA
Ericksen
M B
MB
Hopfer
H
H
Xiao
Y
Y
Stillman
I E
IE
Kalluri
R
R
D020533:Angiogenesis Inhibitors / Q000633:toxicity*; D000818:Animals; D000970:Antineoplastic Agents / Q000633:toxicity*; D017209:Apoptosis; D001324:Autoantigens / Q000633:toxicity*; D001485:Basement Membrane / Q000737:chemistry / Q000502:physiology*; D002292:Carcinoma, Renal Cell / Q000098:blood supply / Q000188:drug therapy / Q000473:pathology*; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D003094:Collagen / Q000737:chemistry / Q000633:toxicity*; D024141:Collagen Type IV; D004338:Drug Combinations; D004730:Endothelium, Vascular / Q000166:cytology / Q000187:drug effects*; D006801:Humans; D007680:Kidney Neoplasms / Q000098:blood supply / Q000188:drug therapy / Q000473:pathology*; D007797:Laminin; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008819:Mice, Nude; D010446:Peptide Fragments / Q000633:toxicity*; D011471:Prostatic Neoplasms / Q000098:blood supply / Q000188:drug therapy / Q000473:pathology*; D011509:Proteoglycans; D011994:Recombinant Proteins / Q000633:toxicity; D014162:Transfection; D014183:Transplantation, Heterologous; D014407:Tumor Cells, Cultured
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D001324:Autoantigens; D024141:Collagen Type IV; D004338:Drug Combinations; D007797:Laminin; D010446:Peptide Fragments; D011509:Proteoglycans; D011994:Recombinant Proteins; C057112:type IV collagen alpha3 chain; C059485:matrigel; D003094:Collagen